(VIANEWS) – Another day of trading has ended and here’s today’s list of stocks that have had significant trading activity in the US session.

The three biggest winners today are Inpixon , Kodiak Sciences, and FuboTV.

The three biggest losers today are Akerna Corp., Tattooed Chef, and Harbor Custom Development.

Winners today

1. Inpixon (INPX) – 23.5%

Inpixon, together with its subsidiaries, provides big data analytics and location based products and related services worldwide. It offers Inpixon Sensor 4000, a passive RF sensor to detect signals ranging from pings to a cell tower to active wireless transmissions; Inpixon IPA Pod offers entry-level barriers to radio detection based indoor positioning; Inpixon Smart School Safety Network solution, a combination of wristbands, ID badges, gateways, and proprietary backend software for school; UWB Sensor Module helps in detection with location; Inpixon GPS 900, a personnel, vehicle, and asset tracking solution; IPA Security, a mobile security and detection product that locates devices operating within a monitored area; Inpixon MDM Connector enables two-way communication between our IPA Security platform and a third-party mobile device management system; Inpixon On-Premises Analytics security customers running systems; and Inpixon GPS Viewer, a browser-based portal used to monitor location and movements of GPS-enabled tracking devices. The company also offers data analytics solutions, such as IPA Wi-Fi, a cloud-based data analytics engine that provides visitor metrics and insights by ingesting diverse data from IoT, third-party, and proprietary sensors; IPA Video analytics to help security personnel combat crime and secure indoor locations; Inpixon Captive Portal, a splash page for their customers to accept terms and conditions before using Wi-Fi; and Shoom Products cloud based applications and analytics for the media and publishing industry. It serves shopping malls, corporate offices, healthcare facilities, government agencies, local publications, and others. The company was formerly known as Sysorex Global and changed its name to Inpixon in March 2017. Inpixon is headquartered in Palo Alto, California.

NASDAQ ended the session with Inpixon jumping 23.5% to $0.25 on Monday while NASDAQ jumped 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Inpixon has a trailing twelve months EPS of $-21.39.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -82.72%.

Volume

Today’s last reported volume for Inpixon is 8456390 which is 31.62% above its average volume of 6424430.

Moving Average

Inpixon ‘s value is way under its 50-day moving average of $0.46 and way below its 200-day moving average of $3.94.

More news about Inpixon .

2. Kodiak Sciences (KOD) – 12.61%

Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in researching, developing, and commercializing therapeutics to treat retinal diseases in the United States and international markets. Its lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biological agent that is in Phase 1b clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy, including diabetic macular edema, as well as for macular edema due to retinal vein occlusion. The company's preclinical stage product candidate includes KSI-501, a bispecific anti-interleukin 6/VEGF bioconjugate conjugate to treat neovascular retinal diseases with an inflammatory component. Its early research pipeline includes KSI-601, a triplet inhibitor for the treatment of multifactorial retinal diseases, such as dry AMD and the neurodegenerative aspects of glaucoma. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was founded in 2009 and is based in Palo Alto, California.

NASDAQ ended the session with Kodiak Sciences jumping 12.61% to $5.27 on Monday, after two successive sessions in a row of losses. NASDAQ jumped 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Kodiak Sciences has a trailing twelve months EPS of $-6.36.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -60.72%.

Volume

Today’s last reported volume for Kodiak Sciences is 599015 which is 55.07% above its average volume of 386273.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 27.3% and 24.1%, respectively.

More news about Kodiak Sciences.

3. FuboTV (FUBO) – 12.5%

fuboTV Inc. operates a live TV streaming platform for live sports, news, and entertainment content in the United States and internationally. Its fuboTV platform allows customers to access content through streaming devices, as well as on SmartTVs, computers, mobile phones, and tablets. The company is headquartered in New York, New York.

NYSE ended the session with FuboTV rising 12.5% to $1.94 on Monday while NYSE rose 0.5% to $15,322.56.

Earnings Per Share

As for profitability, FuboTV has a trailing twelve months EPS of $-1.68.

More news about FuboTV.

4. Genasys (GNSS) – 11.49%

Genasys Inc., a communication company, designs, develops, and commercializes directed and multidirectional sound technologies, voice broadcast products, and location-based mass messaging solutions for emergency warning and workforce management worldwide. The company operates through two segments, Hardware and Software. It provides long range acoustic devices, such as acoustic hailing devices which are used to project sirens and audible voice messages; and Genasys Emergency Management, a unified software platform for cloud, on-premise or hybrid operations. The company also offers Integrated Mass Notification Solutions, including Genasys voice arrays, which project sirens and audible voice messages 60° – 360° with vocal clarity from close range to approximately 14 square kilometers; and GEM software to deliver SMS, text, email, and social media alerts to people at risk in defined geographic areas. It sells its products directly to governments, militaries, end-users, and commercial companies. The company was formerly known as LRAD Corporation. Genasys Inc. is based in San Diego, California.

NASDAQ ended the session with Genasys jumping 11.49% to $2.62 on Monday, following the last session’s upward trend. NASDAQ rose 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Genasys has a trailing twelve months EPS of $-0.48.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Genasys’s EBITDA is -46.43.

More news about Genasys.

5. Western Digital (WDC) – 9.46%

Western Digital Corporation develops, manufactures, and sells data storage devices and solutions in the United States, China, Hong Kong, Europe, the Middle East, Africa, rest of Asia, and internationally. It offers client devices, including hard disk drives (HDDs) and solid state drives (SSDs) for computing devices, such as desktop and notebook personal computers (PCs), smart video systems, gaming consoles, and set top boxes; flash-based embedded storage products for mobile phones, tablets, notebook PCs, and other portable and wearable devices, as well as automotive, Internet of Things, industrial, and connected home applications; and flash-based memory wafers. The company also provides enterprise helium hard drives; enterprise SSDs consisting of flash-based SSDs and software solutions for use in enterprise servers, on-line transactions, data analysis, and other enterprise applications; drives are used for data storage systems and tiered storage models; and data storage platforms. In addition, it offers client solutions, such as external HDD storage products in mobile and desktop form; client portable SSDs; removable cards that are used in consumer devices comprising mobile phones, tablets, imaging systems, and cameras and smart video systems; universal serial bus flash drives for use in the computing and consumer markets; and wireless drive products used in-field back up of created content, as well as wireless streaming of high-definition movies, photos, music, and documents to tablets, smartphones, and PCs. The company sells its products under the Western Digital, SanDisk, and WD brands to original equipment manufacturers, distributors, dealers, resellers, and retailers. Western Digital Corporation was founded in 1970 and is headquartered in San Jose, California.

NASDAQ ended the session with Western Digital rising 9.46% to $36.15 on Monday while NASDAQ jumped 0.66% to $12,365.21.

: western digital stock leads S&P 500 gainers on kioxia merger reportWestern Digital Corp. shares led gainers on the S&P 500 index Monday after a report said inventory problems are hastening merger talks between the data-storage company and Japan-based partner Kioxia Holdings Corp. Western Digital shares surged 12% Monday after .

Earnings Per Share

As for profitability, Western Digital has a trailing twelve months EPS of $-2.21.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -5.64%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is a negative 213.5% and a negative 740%, respectively.

More news about Western Digital.

6. Immatics N.V. (IMTXW) – 8.2%

NASDAQ ended the session with Immatics N.V. jumping 8.2% to $2.77 on Monday, after five consecutive sessions in a row of losses. NASDAQ rose 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Yearly Top and Bottom Value

Immatics N.V.’s stock is valued at $2.77 at 17:32 EST, below its 52-week low of $2.77.

More news about Immatics N.V..

7. Heico Corporation (HEI) – 7.73%

HEICO Corporation, through its subsidiaries, designs, manufactures, and sells aerospace, defense, and electronic related products and services. The company's Flight Support Group segment provides jet engine and aircraft component replacement parts; thermal insulation blankets and parts; renewable/reusable insulation systems; and specialty components. This segment also distributes hydraulic, pneumatic, structural, interconnect, mechanical, and electro-mechanical components for the commercial, regional, and general aviation markets; and offers repair and overhaul services for jet engine and aircraft component parts, avionics, instruments, composites, and flight surfaces of commercial aircraft, as well as for avionics and navigation systems, subcomponents, and other instruments utilized on military aircraft. Its Electronic Technologies Group segment provides electro-optical infrared simulation and test equipment; electro-optical laser products; electro-optical, microwave, and other power equipment; electromagnetic and radio frequency (RF) interference shielding and suppression filters; power conversion and interface products; interconnection devices; power electronics; and underwater locator beacons and emergency locator transmission beacons. This segment also offers traveling wave tube amplifiers and microwave power modules; memory products and specialty semiconductors; harsh environment connectivity products and custom molded cable assemblies; RF and microwave products; communications and electronic intercept receivers and tuners; self-sealing auxiliary fuel systems; active antenna systems and airborne antennas; nuclear radiation detectors; silicone products; power amplifiers; ceramic-to-metal feedthroughs and connectors; technical surveillance countermeasures equipment; RF receivers and sources; embedded computing solutions; test sockets and adapters; and radiation assurance services. The company was founded in 1957 and is headquartered in Hollywood, Florida.

NYSE ended the session with Heico Corporation jumping 7.73% to $178.79 on Monday, after three sequential sessions in a row of losses. NYSE jumped 0.5% to $15,322.56, after four successive sessions in a row of losses, on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Heico Corporation has a trailing twelve months EPS of $2.59.

PE Ratio

Heico Corporation has a trailing twelve months price to earnings ratio of 69.03. Meaning, the purchaser of the share is investing $69.03 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.05%.

Yearly Top and Bottom Value

Heico Corporation’s stock is valued at $178.79 at 17:32 EST, higher than its 52-week high of $177.55.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Heico Corporation’s EBITDA is 130.47.

Sales Growth

Heico Corporation’s sales growth is 25.5% for the present quarter and 22.1% for the next.

More news about Heico Corporation.

8. Atlassian (TEAM) – 7.6%

Atlassian Corporation, through its subsidiaries, designs, develops, licenses, and maintains various software products worldwide. Its products include Jira Software and Jira Work Management, a workflow management system for teams to plan, track, collaborate, and manage work, and projects; Jira Service Management, a service desk product for creating and managing service experiences for various service team providers, including IT, legal, and HR teams; Jira Align for enterprise organizations to build and manage a master plan that maps strategic projects to the various work streams required to deliver them; and Opsgenie, an incident management tool that enables IT teams to plan for and respond to service disruptions. The company also provides Confluence, a social and flexible content collaboration platform used to create, share, organize, and discuss projects; and Trello, a collaboration and organization product that captures and adds structure to fluid, fast-forming work for teams. In addition, it offers Bitbucket, a code management and collaboration product for teams using distributed version control systems; Atlassian Access, an enterprise-wide product for enhanced security and centralized administration that works across every Atlassian cloud product used, including Jira, Jira Service Management, Confluence, Trello, and Bitbucket; and various other products, such as Atlassian cloud apps, Bamboo, Crowd, Crucible, Fisheye, Halp, Sourcetree, and Statuspage. Atlassian Corporation was founded in 2002 and is headquartered in Sydney, Australia.

NASDAQ ended the session with Atlassian jumping 7.6% to $145.29 on Monday, after two successive sessions in a row of losses. NASDAQ jumped 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat positive trend trading session today.

Earnings Per Share

As for profitability, Atlassian has a trailing twelve months EPS of $-2.35.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -138.51%.

Sales Growth

Atlassian’s sales growth is 20.4% for the present quarter and 18.4% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 23.6%, now sitting on 3.36B for the twelve trailing months.

More news about Atlassian.

9. Sabre Corporation (SABR) – 7.5%

Sabre Corporation, through its subsidiaries, provides software and technology solutions for the travel industry worldwide. It operates in two segments, Travel Solutions and Hospitality Solutions. The Travel Solutions segment operates a business-to-business travel marketplace that offers travel content, such as inventory, prices, and availability from a range of travel suppliers, including airlines, hotels, car rental brands, rail carriers, cruise lines, and tour operators with a network of travel buyers comprising online and offline travel agencies, travel management companies, and corporate travel departments. This segment also provides a portfolio of software technology products and solutions through software-as-a-service (SaaS) and hosted delivery models to airlines and other travel suppliers. Its products include reservation systems for carriers, commercial and operations products, agency solutions, and data-driven intelligence solutions. The Hospitality Solutions segment provides software and solutions to hoteliers through SaaS and hosted delivery models. Sabre Corporation was incorporated in 2006 and is headquartered in Southlake, Texas.

NASDAQ ended the session with Sabre Corporation rising 7.5% to $3.44 on Monday, after four consecutive sessions in a row of losses. NASDAQ jumped 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Sabre Corporation has a trailing twelve months EPS of $-1.74.

Moving Average

Sabre Corporation’s worth is way under its 50-day moving average of $4.05 and way below its 200-day moving average of $5.67.

Sales Growth

Sabre Corporation’s sales growth is 8.6% for the current quarter and 9.2% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 27%, now sitting on 2.69B for the twelve trailing months.

Volatility

Sabre Corporation’s last week, last month’s, and last quarter’s current intraday variation average was a negative 3.85%, a negative 1.22%, and a positive 2.93%.

Sabre Corporation’s highest amplitude of average volatility was 3.85% (last week), 2.40% (last month), and 2.93% (last quarter).

More news about Sabre Corporation.

10. Bilibili (BILI) – 7.5%

Bilibili Inc. provides online entertainment services for the young generations in the People's Republic of China. Its platform offers a range of content, including video services, mobile games, and value-added service, as well as ACG-related comic and audio content. The company's video services include professional user generated videos, occupationally generated videos, live broadcasting, and story mode. Bilibili Inc. was founded in 2009 and is headquartered in Shanghai, the People's Republic of China.

NASDAQ ended the session with Bilibili rising 7.5% to $19.58 on Monday while NASDAQ rose 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Bilibili has a trailing twelve months EPS of $-2.65.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -40.63%.

Growth Estimates Quarters

The company’s growth estimates for the present quarter and the next is 33.9% and 47.8%, respectively.

Yearly Top and Bottom Value

Bilibili’s stock is valued at $19.58 at 17:32 EST, way under its 52-week high of $30.35 and way higher than its 52-week low of $8.23.

Revenue Growth

Year-on-year quarterly revenue growth grew by 6.3%, now sitting on 21.9B for the twelve trailing months.

More news about Bilibili.

Losers Today

1. Akerna Corp. (KERNW) – -65.91%

NASDAQ ended the session with Akerna Corp. sliding 65.91% to $0.00 on Monday while NASDAQ rose 0.66% to $12,365.21.

More news about Akerna Corp..

2. Tattooed Chef (TTCF) – -38.25%

Tattooed Chef, Inc., a plant-based food company, produces and sells a portfolio of frozen foods. It supplies plant-based products to retailers in the United States. The company offers ready-to-cook bowls, zucchini spirals, riced cauliflower, acai and smoothie bowls, cauliflower crust pizza, and plant-based burgers. Its products are available in private label and Tattooed Chef brand name in the frozen food section of retail food stores. As of December 31, 2021, it operated approximately 14,000 retail outlets. Tattooed Chef, Inc. is headquartered in Paramount, California.

NASDAQ ended the session with Tattooed Chef dropping 38.25% to $0.80 on Monday while NASDAQ jumped 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Tattooed Chef has a trailing twelve months EPS of $-1.07.

More news about Tattooed Chef.

3. Harbor Custom Development (HCDI) – -31.19%

Harbor Custom Development, Inc. engages in the real estate development business in Western Washington's Puget Sound region. The company undertakes projects, such as residential lots, home communities, and single family and multi-family properties. It is involved in the land development cycle activities, including land acquisition, entitlements, construction of project infrastructure, home building, marketing, sales, and management of various residential projects. The company was formerly known as Harbor Custom Homes, Inc. and changed its name to Harbor Custom Development, Inc. in August 2019. Harbor Custom Development, Inc. was founded in 2014 and is headquartered in Gig Harbor, Washington.

NASDAQ ended the session with Harbor Custom Development dropping 31.19% to $6.00 on Monday while NASDAQ rose 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Harbor Custom Development has a trailing twelve months EPS of $-59.87.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -19.31%.

Growth Estimates Quarters

The company’s growth estimates for the ongoing quarter and the next is a negative 213.3% and a negative 810%, respectively.

Yearly Top and Bottom Value

Harbor Custom Development’s stock is valued at $6.00 at 17:32 EST, way below its 52-week high of $45.00 and way above its 52-week low of $3.15.

More news about Harbor Custom Development.

4. Harrow Health (HROW) – -18.58%

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.

NASDAQ ended the session with Harrow Health falling 18.58% to $22.04 on Monday while NASDAQ jumped 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Harrow Health has a trailing twelve months EPS of $-0.51.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -73.8%.

Sales Growth

Harrow Health’s sales growth is 23.5% for the current quarter and 63.8% for the next.

Revenue Growth

Year-on-year quarterly revenue growth grew by 0.7%, now sitting on 88.59M for the twelve trailing months.

Growth Estimates Quarters

The company’s growth estimates for the present quarter is 100% and a drop 45.8% for the next.

More news about Harrow Health.

5. Jaguar Health (JAGX) – -16.95%

Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. It operates through two reportable segments, Human Health and Animal Health. The company, through its subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. It markets Mytesi, a crofelemer 125 mg delayed-release tablet for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. It develops Mytesi for multiple possible follow-on indications, including diarrhea related to targeted cancer therapy; orphan-drug indications for infants and children with congenital diarrheal disorders and short bowel syndrome; supportive care for inflammatory bowel disease; irritable bowel syndrome; and for idiopathic/functional diarrhea, as well as a second-generation proprietary anti-secretory agent is in development for cholera. The company also develops Crofelemer, a drug product candidate for chemotherapy-induced diarrhea in dogs. Jaguar Health, Inc. was incorporated in 2013 and is headquartered in San Francisco, California.

NASDAQ ended the session with Jaguar Health falling 16.95% to $0.81 on Monday while NASDAQ jumped 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Jaguar Health has a trailing twelve months EPS of $-36.01.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -922.07%.

Sales Growth

Jaguar Health’s sales growth is 56.7% for the ongoing quarter and 48.6% for the next.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Jaguar Health’s EBITDA is -7.1.

Revenue Growth

Year-on-year quarterly revenue growth grew by 56.7%, now sitting on 11.96M for the twelve trailing months.

Yearly Top and Bottom Value

Jaguar Health’s stock is valued at $0.81 at 17:32 EST, way below its 52-week high of $32.63 and way higher than its 52-week low of $0.46.

More news about Jaguar Health.

6. Helius Medical Technologies (HSDT) – -12.31%

Helius Medical Technologies, Inc., a neurotechnology company, focuses on developing, licensing, and acquiring non-invasive technologies for the treatment of symptoms caused by neurological disease or trauma. Its product, Portable Neuromodulation Stimulator (PoNS), is a non-implantable investigational medical device intended for use as a short term treatment of gait deficit due to symptoms from multiple sclerosis and balance deficit due to mild-to-moderate traumatic brain injury, as well as to be used in conjunction with supervised therapeutic exercise. The company is headquartered in Newtown, Pennsylvania.

NASDAQ ended the session with Helius Medical Technologies sliding 12.31% to $0.15 on Monday while NASDAQ rose 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Helius Medical Technologies has a trailing twelve months EPS of $-0.91.

Yearly Top and Bottom Value

Helius Medical Technologies’s stock is valued at $0.15 at 17:32 EST, way below its 52-week high of $2.76 and above its 52-week low of $0.14.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Helius Medical Technologies’s EBITDA is 3.

More news about Helius Medical Technologies.

7. Glory Star New Media Group Holdings Limited (GSMGW) – -11.54%

Glory Star New Media Group Holdings Limited provides advertisement and content production services in China. The company also engages in the mobile and online advertising, digital media, and entertainment businesses. In addition, it offers CHEERS app, an e-commerce platform, which provides online store, live streaming, and online games, as well as online short videos, variety shows, and dramas. Glory Star New Media Group Holdings Limited was founded in 2016 and is headquartered in Beijing, China.

NASDAQ ended the session with Glory Star New Media Group Holdings Limited sliding 11.54% to $0.01 on Monday, after five sequential sessions in a row of losses. NASDAQ jumped 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat up trend trading session today.

Earnings Per Share

As for profitability, Glory Star New Media Group Holdings Limited has a trailing twelve months EPS of $0.54.

PE Ratio

Glory Star New Media Group Holdings Limited has a trailing twelve months price to earnings ratio of 0.02. Meaning, the purchaser of the share is investing $0.02 for every dollar of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 15.93%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 7.4%, now sitting on 157.08M for the twelve trailing months.

More news about Glory Star New Media Group Holdings Limited.

8. Gossamer Bio (GOSS) – -11.11%

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor 2, which is in Phase IIb clinical trial for the treatment of moderate-to-severe eosinophilic asthma; in Phase II clinical trial to treat patients with chronic rhinosinusitis with and without nasal polyps; and in Phase 2 clinical trial in patients with chronic spontaneous urticarial. The company is also developing GB002, an orally inhaled, small molecule, platelet-derived growth factor receptor kinase inhibitor in Phase Ib clinical trial for the treatment of pulmonary arterial hypertension; GB004, a gut-targeted, oral small molecule in Phase Ib clinical trial for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; and GB1275, an oral, small molecule, CD11b modulator in Phase 1/2 clinical trial for the treatment of selected solid tumor types. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds; and Aerpio Pharmaceuticals, Inc. to develop and commercialize GB004 and related compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

NASDAQ ended the session with Gossamer Bio sliding 11.11% to $1.20 on Monday, after two sequential sessions in a row of losses. NASDAQ rose 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat bullish trend trading session today.

Earnings Per Share

As for profitability, Gossamer Bio has a trailing twelve months EPS of $-2.41.

Yearly Top and Bottom Value

Gossamer Bio’s stock is valued at $1.20 at 17:32 EST, way below its 52-week high of $15.20 and way above its 52-week low of $0.91.

Moving Average

Gossamer Bio’s worth is below its 50-day moving average of $1.24 and way under its 200-day moving average of $6.42.

Volume

Today’s last reported volume for Gossamer Bio is 2122110 which is 36.2% below its average volume of 3326400.

Earnings Before Interest, Taxes, Depreciation, and Amortization

Gossamer Bio’s EBITDA is -2.48.

More news about Gossamer Bio.

9. Gritstone Oncology (GRTS) – -9.96%

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was founded in 2015 and is headquartered in Emeryville, California.

NASDAQ ended the session with Gritstone Oncology sliding 9.96% to $2.35 on Monday while NASDAQ rose 0.66% to $12,365.21.

Earnings Per Share

As for profitability, Gritstone Oncology has a trailing twelve months EPS of $-1.17.

Volume

Today’s last reported volume for Gritstone Oncology is 735267 which is 39.34% above its average volume of 527646.

Yearly Top and Bottom Value

Gritstone Oncology’s stock is valued at $2.35 at 17:32 EST, way under its 52-week high of $5.85 and way higher than its 52-week low of $1.71.

Growth Estimates Quarters

The company’s growth estimates for the current quarter is 2.9% and a drop 2.9% for the next.

Sales Growth

Gritstone Oncology’s sales growth is negative 41.9% for the present quarter and negative 11.4% for the next.

More news about Gritstone Oncology.

10. Harpoon Therapeutics (HARP) – -9.77%

Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead tri-specific t-cell activating construct (TriTAC) product candidate is HPN424, which is in Phase I/IIa clinical trials for the treatment of metastatic castration-resistant prostate cancer. It is also developing HPN536, which is in Phase I/IIa clinical trials for the treatment of ovarian cancer and other mesothelin-expressing tumors; HPN217 that is in Phase I/II clinical trials for the treatment of multiple myeloma; and HPN328, a product candidate in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors. The company has a discovery collaboration and license agreement with AbbVie Biotechnology Ltd. to develop and commercialize products that incorporate our proprietary TriTAC platform technology together with soluble T cell receptors. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.

NASDAQ ended the session with Harpoon Therapeutics dropping 9.77% to $0.74 on Monday, following the last session’s downward trend. NASDAQ jumped 0.66% to $12,365.21, following the last session’s downward trend on what was a somewhat up trend exchanging session today.

Earnings Per Share

As for profitability, Harpoon Therapeutics has a trailing twelve months EPS of $-2.46.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -213.43%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 5.5%, now sitting on 31.91M for the twelve trailing months.

Volume

Today’s last reported volume for Harpoon Therapeutics is 301856 which is 24.02% above its average volume of 243375.

More news about Harpoon Therapeutics.

Stay up to date with our winners and losers daily report